Literature DB >> 21501905

[Efficacy and safety of high dose (≥8 mg/kg/day) daptomycin].

Jorge Parra-Ruiz1, Alejandro Peña-Monje, Cristina Tomás-Jiménez, José Pomares-Mora, José Hernández-Quero.   

Abstract

INTRODUCTION: There is a paucity of data regarding efficacy and safety of high dose (>8mg/kg/day) daptomycin.
MATERIAL AND METHODS: This ambispective study included all patients that received ≥8 mg/kg/day of daptomycin and had efficacy and safety data.
RESULTS: Sixty-nine patients were included. Fifty-nine patients (85.5%) were recorded as having been cured or improved. Six patients (8.6%) had a raised CPK during follow-up with no clinical signs of myopathy in any of them.
CONCLUSIONS: High dose daptomycin shows good efficacy without concerns about toxicity.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21501905     DOI: 10.1016/j.eimc.2011.02.012

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  5 in total

1.  Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy.

Authors:  J Parra-Ruiz; C Dueñas-Gutiérrez; C Tomás-Jiménez; J P Linares-Palomino; J Garrido-Gomez; J Hernández-Quero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-08       Impact factor: 3.267

2.  Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Authors:  B J Werth; M E Steed; C E Ireland; T T Tran; P Nonejuie; B E Murray; W E Rose; G Sakoulas; J Pogliano; C A Arias; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Tolerability of High Doses of Daptomycin in the Treatment of Prosthetic Vascular Graft Infection: A Retrospective Study.

Authors:  Laurence Legout; Piervito D'Elia; Beatrice Sarraz-Bournet; Nicolas Ettahar; Stephan Haulon; Olivier Leroy; Eric Senneville
Journal:  Infect Dis Ther       Date:  2014-09-04

4.  Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.

Authors:  R Andrew Seaton; Francesco Menichetti; Georgios Dalekos; Andres Beiras-Fernandez; Francisco Nacinovich; Rashidkhan Pathan; Kamal Hamed
Journal:  Adv Ther       Date:  2015-11-26       Impact factor: 3.845

5.  Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections.

Authors:  Artur Timerman; Carlos Brites; Eliana Bicudo; Renato S Grinbaum; Rubens Costa Filho; Claudia D M Carrilho; Andre Bichels; Tânia Barreto
Journal:  Braz J Infect Dis       Date:  2013-07-31       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.